In a report released today, Serge Belanger from Needham maintained a Buy rating on Cytokinetics, with a price target of $72.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger’s rating is based on several factors, including the ongoing regulatory reviews for Cytokinetics’ drug, afi, in major markets such as the U.S., Europe, and China. The upcoming PDUFA date on December 26, 2025, is a focal point for investors, as the outcome could influence the product’s market positioning against competitors like Camzyos. While there may not be significant differentiation in the product label, the choice between afi and its competitors might depend on healthcare provider preferences and payer access or reimbursement strategies.
Additionally, the MAPLE-HCM trial, which compares afi to metoprolol, could be crucial in establishing afi’s role as a first-line treatment, potentially impacting treatment guidelines and reimbursement policies. Another opportunity for afi’s differentiation lies in the nHCM market, with the ACACIA-HCM trial providing further insights. These factors contribute to the Buy rating and the price target of $72, as they suggest potential for afi’s market success and strategic advantages.
Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Trevi Therapeutics, and BioCryst. According to TipRanks, Belanger has an average return of 2.8% and a 44.00% success rate on recommended stocks.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a $80.00 price target.